Alpha N, Beta S - Acids Or Salts Thereof Patents (Class 562/557)
  • Publication number: 20150147411
    Abstract: The present invention relates to a composition for preventing or treating colitis. According to one embodiment of the present invention, the composition for preventing or treating colitis comprises S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the same as an active ingredient, and exhibits an anti-inflammatory action in colitis. The composition for preventing or treating colitis has outstanding effects in preventing and alleviating colitis due to the effect of the anti-inflammatory action and the effect of an antioxidant action of S-allyl-L-cysteine, while at the same time S-allyl-L-cysteine is not accompanied by side-effects, therefore, has a wide scope of use against colitis.
    Type: Application
    Filed: July 3, 2013
    Publication date: May 28, 2015
    Applicant: PHARMAKING CO., LTD.
    Inventors: Soon Bae Kim, Gwang Soon Kim, Wan Bae Kim, Wie Jong Kwak, Sun Duck Jeon, Hyung Young Yoon, Ki Baik Hahm, Eun Hee Kim
  • Patent number: 8968791
    Abstract: The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 3, 2015
    Assignee: Novus International, Inc.
    Inventors: Jeremy D. Moore, Thomas R. Hampton, Robert Harrell
  • Publication number: 20150038577
    Abstract: A nutritional supplement for a human, the supplement having a chelate comprised of an N-acetyl-L-cysteine ligand bonded to a metal to form a chelate ring. A method for preparing a chelate comprised of N-acetyl-L-cysteine ligand and a metal having the steps of: dissolving an amount of N-acetyl-L-cysteine in an aqueous solution, adding a metal to the aqueous solution, stifling and heating the aqueous solution, and removing the solvent under reduced pressure. A method of treating a human for one or more of oxidative stress, cardiovascular disease, cerebrovascular disease, neurodegenerative diseases, Alzheimer's disease, ADHD, bipolar, schizophrenia, autism, dementia, and HIV in a human comprising administering an effective amount of a composition having N-acetyl-L-cysteine in a chelate formation with a metal. A compound having a chelate formulation with a metal being chelated by an N-acetyl-L-cysteine ligand.
    Type: Application
    Filed: December 27, 2013
    Publication date: February 5, 2015
    Inventors: Xueju Xie, Rhett Sean Daniels, Patricia Gahan
  • Publication number: 20140243282
    Abstract: The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions.
    Type: Application
    Filed: December 12, 2011
    Publication date: August 28, 2014
    Inventor: Satish Reddy Kallam
  • Publication number: 20140205846
    Abstract: Described herein are multi-dimensional networks that can include a recurring unit of Formula (I) and a recurring unit of Formula (II), and methods of synthesizing and using the same.
    Type: Application
    Filed: December 21, 2011
    Publication date: July 24, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Eric McFarland, Omar Yaghi, Hexiang Deng, Dani Peri
  • Patent number: 8653136
    Abstract: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided, in particular methionine, phenylalanine, histidine, tryphtophan, as well as non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e., cystine and cysteine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: February 18, 2014
    Assignee: Determinants of Metabolism Research Laboratory S.R.L.
    Inventors: Franco Conti, Francesco Saverio Dioguardi
  • Patent number: 8637573
    Abstract: The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyclic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: January 28, 2014
    Assignee: Iasomai AB
    Inventors: Tiziana Parasassi, Maria Grazia Porpora
  • Publication number: 20140024715
    Abstract: The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a ?-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same.
    Type: Application
    Filed: April 23, 2013
    Publication date: January 23, 2014
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventor: Darryl R. PETERSON
  • Publication number: 20140024857
    Abstract: Cysteine amino-acid compound (or its analogues) used in the disruption of microbial biofilms by treatment of prevention of diseases generated by phytopathogenic bacteria attacking plants of agricultural interest represented by an innovative solution within the agriculture sector, where said compound can be used in the pharmacological form, as a drug associated with fertilizer for the combat of bacterial diseases which form microbial biofilms, such as citrus variegated chlorosis (CVC), citric canker’, huanlongbing (HLB) disease or ‘greening’, amongst other, which inventive concept, as such, never before completed, resides in the benefit deriving from the cysteine amino-acid, and all of its analogues, in the inhibitory action and progressive disruption of the microbial biofilm thus liberating the nutritive flux and hydration of the root to the upper part of the plant and the subsequent regression of the disease symptoms, with the added advantage that the cysteine amino-acid compound is non-toxic, guaranteeing h
    Type: Application
    Filed: January 9, 2012
    Publication date: January 23, 2014
    Applicant: INSTITUTO AGRONOMICO DE CAMPINAS - IAC
    Inventor: Alessandra Alves De Souza
  • Publication number: 20140018423
    Abstract: The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 16, 2014
    Applicant: CYTACOAT AB
    Inventors: Anders Wirsen, Birgitta Agerberth, Gudmundur Gudmundsson, Jacob Odeberg, Torbjorn Lindberg
  • Patent number: 8604237
    Abstract: Subject of the invention is a method for the production of L-carnitine, comprising the steps of (a) providing a solution comprising at least 5% (w/w) carnitine in a first solvent, wherein the carnitine is a mixture of D- and L-carnitine, (b) optionally seeding the solution with L-carnitine crystals, (c) adding an second solvent, in which the L-carnitine is not soluble or has a low solubility, (d) isolating crystals comprising L-carnitine.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: December 10, 2013
    Assignee: Lonza Ltd
    Inventors: Thomas Büchner, Gesa Paradies
  • Patent number: 8581001
    Abstract: A metformin-cysteine prodrug. It is believed that the prodrug of the present invention will transport in the LAT1 and LAT2 transporter system. Because the LAT1 and LAT2 transporters are important and effective transporters of amino acids in both the small intestine and colon, it is believed that the LAT-transportable prodrugs of the present invention will be effectively absorbed both in small intestine and in the colon. The increased absorption window provided by the present invention should result in highly sustained plasma concentrations of metformin, thereby increasing the effectiveness of the medication and allowing for a single daily dose.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: November 12, 2013
    Assignee: Codman & Shurtleff
    Inventor: Thomas M. DiMauro
  • Publication number: 20130281726
    Abstract: To provide a method for recovering a precious metal from a solution containing precious metal ions, an extracting agent or adsorbent used therefor, and a back-extracting agent or desorbent. An extracting agent or adsorbent in which precious metal ions are extracted or adsorbed, is brought into contact with a back-extracting agent or desorbent containing a sulfur-containing amino acid derivative represented by the following formula (I): wherein R1 is a methyl group, an ethyl group, a vinyl group, a C3-8 linear, branched or cyclic hydrocarbon group, or a C6-14 aromatic hydrocarbon group, R2's are each independently a hydrogen atom, a methyl group, an ethyl group, a vinyl group, a C3-8 linear, branched or cyclic hydrocarbon group or a C6-14 aromatic hydrocarbon group, and n is 0 or 1, to obtain a solution containing the precious metal ions, which is subjected to a reduction treatment to obtain a precious metal.
    Type: Application
    Filed: December 28, 2011
    Publication date: October 24, 2013
    Applicant: TOSOH CORPORATION
    Inventors: Yukinori Suso, Takashi Sakaki
  • Patent number: 8501242
    Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.
    Type: Grant
    Filed: May 29, 2010
    Date of Patent: August 6, 2013
    Assignee: University of Florida Research Foundation
    Inventors: David A. Ostrov, Carmen J. Allegra
  • Publication number: 20130172418
    Abstract: The present disclosure relates to a composition for treating anxiety disorder, particularly to a pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder such as post traumatic stress disorder or phobia. In accordance with the present disclosure, N-acetyl-L-cysteine can block the renewal of fear memories for a sustained period of time when it was administered during or after an exposure therapy to treat post traumatic stress disorder or phobia.
    Type: Application
    Filed: September 6, 2010
    Publication date: July 4, 2013
    Inventors: Suk Woo Choi, Suk Won Lee, Jeong Yeon Kim, Beom Jong Song, In Gie Hong, Sung Mo Park, Ji Hye Kim, Jun Uk Lee, Bo Bae An
  • Patent number: 8475775
    Abstract: The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: July 2, 2013
    Assignee: The UAB Research Foundation
    Inventors: Wayne J. Brouillette, Donald D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Ruppert
  • Publication number: 20130165515
    Abstract: Divalent salts of S-allylmercapto-N-acetylcysteine and related compositions are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compositions include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.
    Type: Application
    Filed: December 3, 2012
    Publication date: June 27, 2013
    Inventor: David Michael Ott
  • Patent number: 8470781
    Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: June 25, 2013
    Assignee: Probiodrug AG
    Inventors: Stephan Schilling, Torsten Hoffmann, Andre Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
  • Publication number: 20130158021
    Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.
    Type: Application
    Filed: October 26, 2012
    Publication date: June 20, 2013
    Applicant: Massachusetts Institute of Technology
    Inventor: Massachusetts Institute of Technology
  • Patent number: 8461204
    Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: June 11, 2013
    Assignee: Signum Biosciences, Inc.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen
  • Publication number: 20130143967
    Abstract: S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.
    Type: Application
    Filed: December 5, 2011
    Publication date: June 6, 2013
    Inventor: David M. Ott
  • Publication number: 20130071439
    Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.
    Type: Application
    Filed: January 10, 2011
    Publication date: March 21, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
  • Publication number: 20130041177
    Abstract: A non-crystalline amorphism of oxidized glutathione is produced by drying a crystal of oxidized glutathione hexahydrate at a temperature of 40 to 90° C.
    Type: Application
    Filed: April 21, 2011
    Publication date: February 14, 2013
    Applicant: KYOWA HAKKO BIO CO., LTD.
    Inventors: Ken Kimura, Kenta Fukumoto, Hiroshi Tanaka
  • Patent number: 8372884
    Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: February 12, 2013
    Assignee: Signum Biosciences, Inc.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
  • Publication number: 20120329846
    Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.
    Type: Application
    Filed: March 27, 2012
    Publication date: December 27, 2012
    Applicant: Ajinomoto Co., Inc.
    Inventors: Hideki Matsumoto, Tomohisa Okutsu, Tomoko Takeda, Hideki Suzuki, Tetsuo Yano, Masaki Hashimoto, Miho Ono, Manabu Suzuki
  • Publication number: 20120328540
    Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.
    Type: Application
    Filed: August 3, 2012
    Publication date: December 27, 2012
    Applicant: SIGNUM BIOSCIENCES, INC.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen
  • Patent number: 8324125
    Abstract: This invention relates to the use of nano-organocatalysts, and, more specifically, to the use of magnetic nanomaterial-supported organocatalysts. It is an object of the present invention to provide “green” catalysts and protocols. According to one embodiment of the invention, a nano-organocatalyst in the form of a magnetic nanomaterial-supported organocatalyst is provided. According to other embodiments of the invention, glutathione and cysteine are provided as organocatalysts and magnetic nanomaterial-supported glutathione and magnetic nanomaterial-supported cysteine are provided for use as nano-organocatalysts. According to another embodiment of the invention, a method of using a recyclable magnetic nanomaterial-supported organocatalyst using a totally benign aqueous protocol, without using any organic solvent in the reaction or during the workup, is provided.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: December 4, 2012
    Assignee: The United States of America as represented by the Administrator of the U.S. Environmental Protection Agency
    Inventors: Rajender S. Varma, Vivek Polshettiwar
  • Publication number: 20120302519
    Abstract: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates.
    Type: Application
    Filed: February 3, 2011
    Publication date: November 29, 2012
    Applicant: MEH ASSOCIATES, INC.
    Inventor: Mark E. Hediger
  • Patent number: 8314140
    Abstract: Derivatives of drugs are provided, said derivatives comprising the H2S-releasing moiety 4-hydroxythiobenzamide that is either covalently linked to the drug or forms a salt with the drug. The compounds of the present invention exhibit enhanced activity or reduced side effects or both.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: November 20, 2012
    Assignee: Antibe Therapeutics Inc.
    Inventors: John Wallace, Giuseppe Cirino, Vincenzo Santagada, Giuseppe Caliendo
  • Publication number: 20120238627
    Abstract: The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyclic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 20, 2012
    Applicant: IASOMAI AB
    Inventors: Tiziana Parasassi, Maria Grazia Porpora
  • Patent number: 8247606
    Abstract: An improved process for preparing Cilastatin Sodium including dissolving Cilastatin acid in a solvent using an organic base, adding sodium salt of a week acid and isolating Cilastatin Sodium.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: August 21, 2012
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Ganapathy Panchapakesan, Nagappan Arumugam, Pandi Suresh Pandian, Gollapalli Venkateswara Rao, Subramaniam Ganesan
  • Publication number: 20120196936
    Abstract: A composition including S-allyl-L-cysteine as an active ingredient and having an anti-Helicobacter pylori activity or a gastric mucosa protective effect, a composition for preventing, relieving, or treating gastrointestinal disorders, and a method of using the compositions.
    Type: Application
    Filed: September 20, 2010
    Publication date: August 2, 2012
    Applicant: PHARMAKING CO., LTD.
    Inventors: Soon Bae Kim, Gwang Soon Kim, Wan Bae Kim, Wie Jong Kwak, Sung Hye Bang
  • Publication number: 20120156212
    Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.
    Type: Application
    Filed: May 29, 2010
    Publication date: June 21, 2012
    Inventors: David A. Ostrov, Carmen J. Allegra
  • Publication number: 20120142941
    Abstract: Disclosed are: a composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily based and is stable and safe; and a pharmaceutical preparation, a cosmetic and a food composition, each of which comprises the composition. The composition for alleviating ultraviolet irradiation-induced damage contains one or more compounds selected from the group consisting of D-glutamic acid, L-glutamic acid, D-proline, D-cystine, L-cystine, and derivatives and/or salts of the aforementioned compounds. The composition can be used as an external formulation for the skin, a cosmetic composition, an anti-wrinkle agent, a sunscreen agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract.
    Type: Application
    Filed: March 30, 2010
    Publication date: June 7, 2012
    Inventors: Yutaka Ashida, Yosuke Tojo, Masashi Mita, Chieko Mizumoto, Shoichiro Shimada, Kayo Matsumoto
  • Publication number: 20120093726
    Abstract: The invention provides compound which is an 18F-radiolabelled S-propylhomocysteine or a derivative thereof. The compound has an enantiomeric purity of at least about 90%. 18F-radiolabelled S-propylhomocysteine may be made by treating an N-protected ester of a substituted S-propylhomocysteine with a complexed F? salt in the presence of a base to form a protected product and then deprotecting the protected product to form the 18F-radiolabelled S-propylhomocysteine. In this method the N-protected ester has a leaving group on the S-propyl group and has an enantiomeric purity of at least about 90%. The base should be such that it does not cause racemisation of the protected product.
    Type: Application
    Filed: March 24, 2009
    Publication date: April 19, 2012
    Inventors: Andrew Katsifis, Christopher John Reginald Fookes, Ivan Greguric, Thomas Bourdier
  • Patent number: 8134026
    Abstract: The present invention relates to an improved process for the preparation of Cilastatin Sodium of formula (I). The present invention also provides an isolation technique for Cilastatin acid from the reaction mixture.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: March 13, 2012
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Ganapathy Panchapakesan, Nagappan Arumugam, Pandi Suresh Pandian, Gollapalli Venkateswara Rao, Subramaniam Ganesan
  • Publication number: 20120041178
    Abstract: Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.
    Type: Application
    Filed: April 6, 2010
    Publication date: February 16, 2012
    Applicant: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bong Hyun Chung, Jung Hyun Han
  • Publication number: 20110312902
    Abstract: The present invention relates generally to the use of ?-glutamyl antioxidants, particularly ?-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The ?-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na/Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943).
    Type: Application
    Filed: April 19, 2011
    Publication date: December 22, 2011
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventor: Darryl R. Peterson
  • Publication number: 20110257432
    Abstract: A metformin-cysteine prodrug. It is believed that the prodrug of the present invention will transport in the LAT1 and LAT2 transporter system. Because the LAT1 and LAT2 transporters are important and effective transporters of amino acids in both the small intestine and colon, it is believed that the LAT-transportable prodrugs of the present invention will be effectively absorbed both in small intestine and in the colon. The increased absorption window provided by the present invention should result in highly sustained plasma concentrations of metformin, thereby increasing the effectiveness of the medication and allowing for a single daily dose.
    Type: Application
    Filed: April 15, 2011
    Publication date: October 20, 2011
    Inventor: Thomas M. DiMauro
  • Publication number: 20110244045
    Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.
    Type: Application
    Filed: May 11, 2009
    Publication date: October 6, 2011
    Applicant: TIARA PHARMACEUTICALS ,INC.
    Inventors: Yadon Arad, Liang C. Dong
  • Publication number: 20110224156
    Abstract: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Inventors: Mark A. Wolf, Keith D. Barnes
  • Publication number: 20110184148
    Abstract: An object of the present invention is to provide a method for synthesizing a peptide thioester by using a compound that can be easily obtained within a relatively short time under conditions in which a side reaction is unlikely to occur. In the present invention, a thioester bond is formed by elongating a peptide chain using N-alkyl cysteine as the C-terminal amino acid according to the Fmoc method, carrying out deprotection, and then causing the peptide bond to undergo N—S transfer to the thiol group of N-alkyl cysteine under weak acidic conditions.
    Type: Application
    Filed: October 5, 2007
    Publication date: July 28, 2011
    Applicant: TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    Inventors: Hironobu Hojo, Yoshiaki Nakahara
  • Publication number: 20110171296
    Abstract: The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.
    Type: Application
    Filed: January 11, 2011
    Publication date: July 14, 2011
    Applicant: Biohit Oyj
    Inventors: Mikko Salaspuro, Martti Marvola
  • Publication number: 20110165098
    Abstract: Compositions and methods to inhibit adverse physiological effects caused by resin-based and resin-containing materials are disclosed. More specifically, the use of N-acetyl-cysteine (NAC) to inhibit hydroxyethyl methacrylate (HEMA)-mediated cell death and cytotoxicity.
    Type: Application
    Filed: December 22, 2010
    Publication date: July 7, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anahid Jewett, Avina Paranjpe
  • Publication number: 20110112192
    Abstract: Use of a pharmaceutically acceptable oxidation or reduction agent for disulfide bridges containing organic compounds for the treatment of odor formation in humans due to the consumption of allium plants or allium plant stuffs.
    Type: Application
    Filed: December 11, 2008
    Publication date: May 12, 2011
    Inventors: Gudrun Pieper, Karl-Heinz Husmann
  • Publication number: 20110054180
    Abstract: This invention relates to the use of nano-organocatalysts, and, more specifically, to the use of magnetic nanomaterial-supported organocatalysts. It is an object of the present invention to provide “green” catalysts and protocols. According to one embodiment of the invention, a nano-organocatalyst in the form of a magnetic nanomaterial-supported organocatalyst is provided. According to other embodiments of the invention, glutathione and cysteine are provided as organocatalysts and magnetic nanomaterial-supported glutathione and magnetic nanomaterial-supported cysteine are provided for use as nano-organocatalysts. According to another embodiment of the invention, a method of using a recyclable magnetic nanomaterial-supported organocatalyst using a totally benign aqueous protocol, without using any organic solvent in the reaction or during the workup, is provided.
    Type: Application
    Filed: September 3, 2009
    Publication date: March 3, 2011
    Applicant: USA as Represented by the Administrator of U.S. Environmental Protection Agency
    Inventors: Rajender S. Varma, Vivek Polshettiwar
  • Publication number: 20110046482
    Abstract: Improved methods of administration of thiol-based agents, such as NAC (N-acetylcysteine) and STS (sodium thiosulfate), are provided that protect against renal and other organ injury caused by diagnostic or therapeutic intra-arterial procedures which employ radiographic contrast agents.
    Type: Application
    Filed: August 16, 2007
    Publication date: February 24, 2011
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Edward A. Neuwelt, Leslie L. Muldoon
  • Publication number: 20110008261
    Abstract: The invention relates to a dynamic nuclear polarisation (DNP) method for producing hyperpolarised amino acids and amino sulphonic acids and compositions for use in the method. As a sample, an ammonium salt of an amino acid, an ammonium salt of an aminosulphonic acid, a carboxylate salt of an amino acid, a sulphonate salt of an aminosulphonic acid or mixtures thereof is used.
    Type: Application
    Filed: February 3, 2009
    Publication date: January 13, 2011
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Mathilde H. Lerche, Magnus Karlsson, Pernille R. Jensen
  • Publication number: 20100305331
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: February 23, 2010
    Publication date: December 2, 2010
    Applicant: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Publication number: 20100272641
    Abstract: Imaging agents that comprise labeled substrates of the cystine/glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine/glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell.
    Type: Application
    Filed: April 27, 2009
    Publication date: October 28, 2010
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: JACK MATHEW WEBSTER, FAISAL AHMED SYUD, BRIAN DUH-LAN LEE, PAUL SCHAFFER, RONG ZHANG, JENNIFER LYNNE HUNTINGTON, KANDE KANKANAMALAGE DAYARATHNA AMARASINGHE